An Advanced Antibody-Based Therapeutics Company

Learn More About Immunomedics

Immunomedics, Inc. Third Quarter Fiscal 2018 Results

On Wednesday, May 9, 2018 at 5:00 p.m. Eastern Time, Immunomedics will host a conference call and webcast to discuss third quarter fiscal 2018 financial results and provide a corporate update.

Our Drive to Improve Targeted Therapies of Diseases

We have assembled significant expertise in antibody engineering, particularly proprietary CDR-grafting methods, antibody production and formulation, immunochemistry, molecular biology, antibody conjugation, peptide chemistry, synthetic organic chemistry, and protein engineering.


We believe that each of our antibodies has therapeutic potential either when administered as a naked antibody or when conjugated with therapeutic radioisotopes (radiolabeled), chemotherapeutics, cytokines or other toxins to create unique and potentially more effective treatment options.

Magnifying glass with people

Explore how we turn our research into reality.

Immunomedics is sponsoring an international Phase 3 clinical trial in patients with relapsed triple-negative breast cancer who have previously received two or more therapies for their metastatic disease.

Clinical Trials